Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of a CHO cell-derived recombinant protein COVID-19 vaccine in adults
ChiCTR2100050849Phase 3Recruiting
- Sponsor
- Sichuan Center for Disease Control and Prevention
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant protein subunit COVID-19 vaccine (CHO cells) in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Sichuan Center for Disease Control and Prevention. Primary endpoints: Protective efficacy against symptomatic virologically confirmed COVID-19 and Incidence of adverse events. Started Sep 2021; status: recruiting.
02
Drugs
recombinant protein subunit COVID-19 vaccine (CHO cells)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100050849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050849.